Screener
Syndax Pharmaceuticals SNDX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Royalty interest financing liability, less current portion | 343,965 | 343,909 |
| Right-of-use liability, less current portion | 907 | 1,051 |
| Total long-term liabilities | 344,872 | 344,960 |
| Total liabilities | 431,046 | 465,076 |
| Commitments and contingencies (Note 15) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized; 88,543,881 and 87,405,979 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 9 | 9 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's total liabilities?
- Syndax Pharmaceuticals (SNDX) reported total liabilities of $431.05M in Q1 2026.
- How has Syndax Pharmaceuticals's total liabilities changed year-over-year?
- Syndax Pharmaceuticals's total liabilities increased by 1.3% year-over-year, from $425.65M to $431.05M.
- What is the long-term trend for Syndax Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's total liabilities has grown at a 57.2% compound annual growth rate (CAGR), from $48.43M to $465.08M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Syndax Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude